EP2205266A2 - Use of the peptide combination thymosin beta 4 ...,https://google.com/patents/EP2205266A2?cl=tr
"WO2009033748A2 - Use of osteostatin, alone or in combination with ...",https://www.google.com/patents/WO2009033748A2?cl=zh
WO2009046877A2 - Use of a histrelin and leuprolide as therapeutic ...,https://www.google.com/patents/WO2009046877A2?cl=pt
"CA2699084A1 - Use of cnp-22, alone1 or in combination with ...",https://www.google.com/patents/CA2699084A1?cl=en
EP2190453A2 - Utilisation de la trp6-triptor√©line et du d-leu6 ...,https://www.google.com/patents/EP2190453A2?cl=fr
EP2187913B1 - Ac-RFMWMR-NH2 for use in the treatment of ...,http://www.google.com/patents/EP2187913B1?cl=un
WO2009046874A1 - Therapeutic combination of trh-potentiating ...,https://www.google.com/patents/WO2009046874A1?cl=pt
EP2187940B1 - Use of urocortin optionally together with ...,https://www.google.com/patents/EP2187940B1?cl=da
CA2699107A1 - Use of a platelet fibrinogen receptor hexapeptide ...,https://www.google.com/patents/CA2699107A1?cl=enIt
US20100184673A1 - Use of parathyroid hormone ( 1-34 ) as anti ...,https://google.com/patents/US20100184673?cl=fr
